News

IMWG issue updated criteria for the diagnosis of myeloma

The International Myeloma Working Group (IMWG) has issued updated criteria for the diagnosis of myeloma. Published online in Lancet Oncology, the latest guidelines allow for the diagnosis of myeloma to be made in asymptomatic patients using three additional validated biomarkers associated with the near inevitable development of clinical symptoms. These additions have the greatest impact…

Details

NICE issue draft ‘no’ to pomalidomide

The National Institute for Health and Care Excellence (NICE) has issued draft guidance not recommending the use of pomalidomide (Imnovid®) in combination with low-dose dexamethasone for relapsed and refractory myeloma patients who have received prior treatment with both Velcade® and Revlimid®. According to NICE, there is insufficient evidence to demonstrate the effectiveness of pomalidomide and low-dose…

Details

New proteasome inhibitor cleared for clinical trials in myeloma

The Swedish pharmaceutical company, Vivolux, has announced that the US Food and Drug Administration (FDA) has granted clearance for its proprietary drug, VLX1570, to begin clinical testing in relapsed and/or refractory myeloma patients. VLX1570 is the first drug in a novel class of proteasome-inhibiting drugs which acts by inhibiting the initiation process that regulates the…

Details

Phase I trial of lirilumab in combination with elotuzumab for myeloma patients commences

Innate Pharma, the French-based biopharmaceutical company, has announced that it will be starting a new Phase I trial of its candidate drug lirilumab in combination with elotuzumab for relapsed and/or refractory myeloma patients. Lirilumab is a fully human monoclonal antibody that blocks the interaction between killer-cell immunoglobulin-like receptors (KIR) on natural killer (NK) cells and…

Details

New trial of measles virotherapy for the treatment of myeloma

Researchers at the Mayo Clinic, Rochester, USA, are starting a new Phase I/II trial of the systemic administration of measles virotherapy with or without cyclophosphamide in relapsed or refractory myeloma patients. The trial will evaluate the safety and efficacy of the edmonston strain of measles virus and follows the successful treatment of a myeloma patient…

Details

Panobinostat offers improved progression-free survival for relapsed and/or refractory myeloma patients

Data from the Phase III Panorama-1 trial have demonstrated a statistically significant and clinically relevant four-month improvement in median progression free survival (PFS) for relapsed and/or refractory myeloma patients receiving panobinostat in combination with Velcade® and dexamethasone compared to Velcade and dexamethasone only. Published in the Lancet Oncology, the authors also found that the benefits of…

Details

Phase I trial of CB-5083 for myeloma patients commences

The US biopharmaceutical company, Cleave Biosciences, has announced it has initiated a new Phase I trial of its lead drug candidate, CB-5083, for the treatment of relapsed and/or refractory myeloma patients. CB-5083 is a first-in-class oral inhibitor of p97, a key enzyme involved with various aspects of protein homeostasis. The dose escalation/expansion trial will evaluate…

Details

High-dose therapy and stem cell transplantation remains the preferred treatment for younger and/or fitter myeloma patients

According to the results of a Phase III trial published recently in the New England Journal of Medicine, high-dose therapy with melphalan followed by stem cell transplantation (HDT-SCT)  is still the preferred treatment for younger and/or fitter myeloma patients, even in the era of novel treatments. In the trial, newly diagnosed patients randomised to consolidation…

Details

FIRST trial results of Revlimid plus dexamethasone for newly diagnosed myeloma patients published

Data from the FIRST trial, an open-label Phase III randomised study have shown that continuous Revlimid and dexamethasone (Rd) treatment for newly diagnosed transplant ineligible myeloma patients significantly improved PFS and overall survival compared to fixed length Rd or standard melphalan, prednisone and thalidomide (MPT) treatment. Based on the results of this trial, Celgene, the…

Details